Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.52 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.52 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.52 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.52 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.52 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24011654 | 0.86 | HDAC1 (0.62) | HDAC1HDAC6GRM5KDM4EPRKAB2 | |
| SCHEMBL5429428 | 0.83 | HDAC1 (0.58) | HDAC1HDAC6KDM4EPRKAB2PRKAG1 | |
| SCHEMBL5423446 | 0.83 | HPGD (0.58) | HDAC1HDAC6KDM4EPRKAB2PRKAG1 | |
| SCHEMBL13164714 | 0.82 | GRM5 (0.56) | GRM5KDM4EMLYCDHPGDSXDH | |
| SCHEMBL5420363 | 0.81 | ALDH1A1 (0.60) | HDAC1HDAC6KDM4EPRKAB2PRKAG1 | |
| SCHEMBL5782817 | 0.81 | HDAC1 (0.55) | HDAC1HDAC6KDM4EPRKAB2PRKAG1 | |
| SCHEMBL9989282 | 0.81 | HDAC1 (0.51) | HDAC1HDAC6KDM4EHPGDALDH1A1 | |
| SCHEMBL7453238 | 0.81 | HDAC1 (0.51) | HDAC1HDAC6KDM4EHPGDALDH1A1 | |
| SCHEMBL6870509 | 0.81 | LMNA (0.60) | GRM5MAPTALDH1A1NPC1LMNA | |
| SCHEMBL21401430 | 0.81 | GRM5 (0.54) | HDAC1HDAC6GRM5MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-08 | — | — | US | claimed |
| EP-1551404-A2 | METHOD OF INHIBITING ANGIOGENESIS | Abbott Laboratories (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040116479-A1 | Method of inhibiting angiogenesis | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | claimed |
| WO-2004032908-A9 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LAB (US) | 2004-05-27 | — | — | WO | claimed |
| WO-2004032908-A2 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | claimed |
| US-20040067985-A1 | Method of inhibiting angiogenesis | ABBOT LABORATORIES | 2004-04-08 | — | — | US | claimed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2022140428-A2 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2016137506-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20070043089-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-22 | — | — | US | disclosed |
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-08 | — | — | US | disclosed |
| EP-1551404-A2 | METHOD OF INHIBITING ANGIOGENESIS | Abbott Laboratories (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040116479-A1 | Method of inhibiting angiogenesis | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
| WO-2004032908-A9 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LAB (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004032908-A2 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040067985-A1 | Method of inhibiting angiogenesis | ABBOT LABORATORIES | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | PGF, VEGFA, FLT4 | HDAC1 439/4885HDAC6 411/4885GRM5 2316/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | HDAC1 51/4885HDAC6 121/4885GRM5 3035/4885 |
| US-20070043089-A1 | METHOD OF INHIBITING ANGIOGENESIS | PGF, VEGFA, FLT4 | HDAC1 439/4885HDAC6 411/4885GRM5 2316/4885 |
| US-20040067985-A1 | Method of inhibiting angiogenesis | VEGFA, PGF, FLT4 | HDAC1 411/4885HDAC6 742/4885GRM5 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.